Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer

European Journal of Cancer

Volumn 50, Issue 9, 2014, Pages 1581-1589

  McNamara, M G ^a   Templeton, A J ^a   Maganti, M ^a   Walter, T ^a,b   Horgan, A M ^a,c   McKeever, L ^a   Min, T ^a   Amir, E ^a   Knox, J J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c WATERFORD REGIONAL HOSPITAL   (Ireland)

Author keywords

Biliary tract cancer; Neutrophil lymphocyte ratio; Prognosis

Indexed keywords

ALBUMIN; BEVACIZUMAB; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

BILIARY TRACT CANCER; NEUTROPHIL/LYMPHOCYTE RATIO; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; BILIARY TRACT SURGICAL PROCEDURES; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PROGNOSIS; YOUNG ADULT;

EID: 84901193502     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.02.015     Document Type: Article

References (36)

1. H.S. Won, M.A. Lee, and E.S. Chung et al. Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer BMC Cancer 10 2010 564
2. A.F. Hezel, V. Deshpande, and A.X. Zhu Genetics of biliary tract cancers and emerging targeted therapies J Clin Oncol 28 2010 3531 3540
3. B.B. Aggarwal, R.V. Vijayalekshmi, and B. Sung Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe Clin Cancer Res 15 2009 425 430
4. C.H. Lee, C.J. Chang, Y.J. Lin, C.N. Yeh, M.F. Chen, and S.Y. Hsieh Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma Br J Cancer 100 2009 1765 1770
5. H.B. El-Serag, E.A. Engels, and O. Landgren et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans Hepatology 49 2009 116 123
6. M.J. Proctor, D.S. Morrison, and D. Talwar et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study Eur J Cancer 47 2011 2633 2641
7. A.J. Templeton, M.G. McNamara, and Vera-Badillo et al. Prognostic role of neutrophil to lymphocyte ratio (nlr) in solid tumors: a systematic review and meta-analysis Eur J Cancer 47 Suppl. 1 2013 [abstract 1008]
8. G.J. Guthrie, K.A. Charles, C.S. Roxburgh, P.G. Horgan, D.C. McMillan, and S.J. Clarke The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer Crit Rev Oncol Hematol 88 2013 218 230
9. Y. Yao, D. Yuan, H. Liu, X. Gu, and Y. Song Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy Cancer Immunol Immunother 62 2013 471 479
10. H.S. Wasan, J.W. Valle, and D.H. Palmer et al. Predictors of survival in patients with advanced biliary tract cancer: results from the UK ABC-02 randomized phase III trial Gastrointest Cancers Symp 2010 [abstract 199]
11. D. Gomez, G. Morris-Stiff, G.J. Toogood, J.P. Lodge, and K.R. Prasad Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma J Surg Oncol 97 2008 513 518
12. T. Dumitrascu, D. Chirita, M. Ionescu, and I. Popescu Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome J Gastrointest Surg 17 2013 913 924
13. P. Bronsert, I. Kohler, and M. Werner et al. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin BMC Cancer 13 2013 428
14. T. Gondo, J. Nakashima, and Y. Ohno et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy Urology 79 2012 1085 1091
15. H.T. Petrie, L.W. Klassen, and H.D. Kay Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes J Immunol 134 1985 230 234
16. A. El-Hag, and R.A. Clark Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system J Immunol 139 1987 2406 2413
17. E. Di Carlo, G. Forni, and P. Musiani Neutrophils in the antitumoral immune response Chem Immunol Allergy 83 2003 182 203
18. H. Schaider, M. Oka, and T. Bogenrieder et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8 Int J Cancer 103 2003 335 343
19. P. Shamamian, J.D. Schwartz, and B.J. Pocock et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis J Cell Physiol 189 2001 197 206
20. P. Scapini, L. Nesi, and M. Mirini et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils J Immunol 168 2002 5798 5804
21. H. Wehbe, R. Henson, F. Meng, J. Mize-Berge, and T. Patel Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression Cancer Res 66 2006 10517 10524
22. F. Meng, Y. Yamagiwa, Y. Ueno, and T. Patel Over expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes J Hepatol 44 2006 1055 1065
23. J. Park, L. Tadlock, G.J. Gores, and T. Patel Inhibition of interleukin-6 mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line Hepatology 30 1999 1128 1133
24. T. Bekaii-Saab, M.A. Phelps, and X. Li et al. Multi-institutional phase II study of Selumetinib in patients with metastatic biliary cancers J Clin Oncol 29 2011 2357 2363
25. Y.T. Tai, M. Fulciniti, and T. Hideshima et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis Blood 110 2007 1656 1663
26. B.B. Aggarwal Nuclear factor-kappa B: the enemy within Cancer Cell 6 2004 203 208
27. K.C. Das, and C.W. White Activation of NF-κB by antineoplastic agents. Role of protein kinase C J Biol Chem 272 1997 14914 14920
28. K.S. Ahn, G. Sethi, and B.B. Aggarwal Nuclear factor-κB: from clone to clinic Curr Mol Med 7 2007 619 637
29. M. Kaneko, H. Nozawa, and K. Sasaki et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy Oncology 82 2012 261 268
30. J. Valle, H. Wasan, and D.H. Palmer et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273 1281
31. National Institutes of Health webpage. ABC-04 a Phase IB study of cisplatin, gemcitabine and selumetinib in patients with advanced biliary tract cancer. Available from: www.ClinicalTrials.gov Identifier: NCT01242605. [Updated 2013 September 26: cited 2013 Nov 13].
32. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
33. J.J. Knox, D. Hedley, and A. Oza et al. Combining gemcitabine and capecitabine (Gem/Cap) in patients with advanced biliary cancer: a phase II trial J Clin Oncol 23 2005 2332 2338
34. R.P. Riechelmann, C.A. Townsley, S.N. Chin, G.R. Pond, and J.J. Knox Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer Cancer 110 2007 1307 1312
35. C.D. Briggs, C.P. Neal, C.D. Mann, W.P. Steward, M.M. Manson, and D.P. Berry Prognostic molecular markers in cholangiocarcinoma: a systematic review Eur J Cancer 45 2009 33 47
36. M.G. McNamara, P. Aneja, L.W. Le, A.M. Horgan, E. McKeever, and J.J. Knox Effects of statin, aspirin or metformin use on recurrence free and overall survival in patients with biliary tract cancer (BTC) Suppl J Clin Oncol 32 Suppl. 3 2014 [abstract 303]